OrthoHelix Surgical Designs Inc.
This article was originally published in Start Up
Executive Summary
OrthoHelix Surgical Designs aims to bring cohesion to the fragmented small bone and joint marketplace. Unlike other small companies in the space, which typically offer products that address a single application, OrthoHelix is building an integrated suite of products designed to address most of the small bone surgeon's needs.
You may also be interested in...
Integra LifeSciences: Mid-Sized Company in Big Company Clothing
Founded in 1989 Integra avoided the sad fates of its peers in tissue engineering (which went bankrupt) by adopting an acquisition strategy that took it into surgical product markets. Integra has enjoyed a compound annual revenue growth rate of 36% since it first embarked on its acquisition strategy in 1999. Its secret of success has been to consolidate fragmented niche markets into which it can create additional value by selling its internally-developed tissue-engineered products. Now, with six operating divisions covering four surgical specialties with a multiplicity of call points, it looks and acts like a large, diversified medical device company. But it's not-with $650 million in revenues, it's a mid-sized company. Can it now, as a mid-sized company with a complicated business, sustain its high level of growth through a combination of acquisitions and organic growth?
Small Bone Innovations LLC
The founders of Small Bone Innovations believes the device industry is entering the decade of small bones and joints, and has embarked on a consolidation strategy to prepare for dramatic innovation and change in what today is a fragmented marketplace.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.